Experts in Arthritis Advisory Committee: Nancy A. Baker, ScD, MPH, OTR/L (Chair); Anita Bemis-Dougherty, PT, DPT, MAS; Leigh Callahan, PhD, Linda Ehrlich-Jones, PhD, RN, Tamara Huff, MD, Irina Konon, MD, Amye L. Leong, MBA, Peggy Lotkowictz, Catherine Morlino, David Neuman, MD, Carol A. Oatis, PT, PhD, Riemond Rippel, Joyce Peck Carlone, MN, RN, CFNP, CCRC, Pam Schroeder, Terrance Starz, MD, Kimberly Templeton, MD
Special thanks to Dr. Garciela Alarcon, MD, MPH, for her assistance with the Spanish language whiteboard videos.
USBJI thanks the Experts in Arthritis collaborating organizations:
American Academy of Pediatrics;
American Association of Occupational Health Nurses;
American Association of Nurse Practitioners;
American College of Rheumatology;
American Legion Auxiliary;
American Medical Women's Association;
American Occupational Therapy Association;
American Physical Therapy Association;
National Association of Colored Women's Clubs;
Center for Disease Control;
Coalition of State Rheumatology Organizations;
National Association of Orthopaedic Nurses;
National Black Nurses Association;
National Hispanic Council on Aging;
National Institute of Arthritis and Musculoskeletal and Skin Diseases;
National Institute of Senior Centers;
Operation Change - Chicago;
Public Library Association;
The USBJI also thanks the following for supporting the Experts in Arthritis program with unrestricted educational grants.
Sanofi Genzyme - Regeneron
The Sanofi Genzyme and Regeneron collaboration is committed to translating cutting-edge science into groundbreaking medicines for patients with serious needs. Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. Since 2007, Regeneron and Sanofi have collaborated to discover, develop, manufacture and commercialize fully human monoclonal antibodies.
Genentech Biogen Idec.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. Genentech has an extensive track record in all phases of bringing new disease treatments to patients from discovery research through clinical development, manufacturing, and commercialization. With multiple protein-based products on the market for serious or life-threatening medical conditions, Genentech has experience taking a drug from A to Z, transforming the seed of an idea in a lab into a novel therapy for a patient in need. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.